EMA Clears Lantern's LP-184 Trial in Biomarker-Selected Bladder Cancer
LTRN has more than doubled off its 52-week low of $1.11 on light trading volume (0.2× avg).
Summary
Lantern Pharma received EMA clearance to start an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in advanced bladder cancer. The study will enroll up to 39 patients at Rigshospitalet in Copenhagen, using a dual biomarker strategy to select those most likely to respond. This is the first clinical trial for LP-184 in bladder cancer, expanding the drug's pipeline beyond the ongoing glioblastoma and other solid tumor programs. The news follows a series of positive developments, including favorable FDA feedback on the LP-300 HARMONIC trial and a recent capital raise, but the company's cash runway remains limited. A clinical signal here could open a large market opportunity in later-line urothelial carcinoma, where effective options are scarce.
At the time of this announcement, LTRN was trading at $2.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $1.11 to $5.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.